Shop by goal

Popular compounds

GHK-Cu Copper Peptide

Retatrutide

Research resources

Tirzepatide péptido de investigación (LY3298176)

Tirzepatide es un agonista dual de los receptores de GIP y de GLP-1 investigado en farmacología de incretinas y señalización metabólica. Los investigadores comparan su perfil de receptores con el de los agonistas de GLP-1 simples y los agonistas triples en investigación. New-U ofrece GLP1-RC-TZ como material de investigación de laboratorio con concentraciones de vial y formatos de pack a elegir. Revise el Certificado de análisis publicado en esta página; no se sugiere equivalencia clínica, seguridad ni eficacia.

For laboratory research only. Not an approved medicine or material for human or veterinary use.

Áreas de investigación publicadas

🧬 Farmacología de receptores

📊 Variables metabólicas

🩸 Variables glucémicas

Product features

Certificate of Analysis Janoshik Analytical report #164666 Tested May 2026. Published online, not packed with orders.

Measured purity 99.899% Result Janoshik Analytical reported for the sample tested.

Vial strengths 5 mg · 10 mg · 15 mg · +10 more 12 of 13 in stock now. Pick one in the selector.

View all product features

Formats Single vial · 10-vial pack Price per vial and pack total update with your selection.

Testing history 2 reports on file Earlier certificates stay published with their own test dates.

This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.

Available in 13 vial strengths, from 5 mg to 120 mg

Dispatched within 24 hours of confirmed payment on business days, shipped worldwide

Third-party tested by Janoshik Analytical

99.899% purity on the latest published report (120 mg vial)

Purity test report: PDF download

Tirzepatide péptido de investigación (LY3298176)

Compare pack sizes

Tap a pack to select it

Single Vials (13)

Buy the 10-pack - save 57%/mg. Single vials welcome — checkout needs 5+ vials or any 10-vial pack - build a custom vial pack

Lab-direct quality — full packs or single-vial samples

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same source, same purity specification — scaled to whatever your research needs.

GLP1-RC-TZ Certificate of Analysis

GLP1-RC-TZ material is analysed by an independent laboratory, and the resulting Certificate of Analysis is published online. A certificate reports what was measured in the sample submitted; vials are not batch-marked, so it is not matched to a particular vial or order.

New-U GLP1-RC-TZ certificate evidence

Catalogue identifier: GLP1-RC-TZ

Independent testing laboratory, report number and test date

Measured purity for the sample analysed

Certificate of Analysis at /coa/tirzepatide; the method and any identity result are stated on the report

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Áreas de investigación publicadas

Los estudios publicados examinan actividad de receptores, farmacocinética y variables metabólicas, glucémicas y de sensibilidad a insulin definidas por protocolo. Los resúmenes siguientes informan de lo que los investigadores midieron en esos estudios externos y no constituyen instrucciones de uso para el material de investigación suministrado aquí.

Farmacología de receptores

Potencia completa en GIPR junto con señalización de GLP-1R sesgada hacia cAMP, caracterizada en estudios in-vitro publicados.

Variables metabólicas

Cambio respecto al valor basal de la masa corporal definido por protocolo, medido en todo el programa SURMOUNT.

Variables glucémicas

HbA1c como variable definida por protocolo, medida en todo el programa de diabetes SURPASS.

Variables de sensibilidad a insulin

Marcadores de sensibilidad a insulin y adiponectin, medidos junto con señalización adiposa directa mediada por GIPR.

Farmacocinética

Exposición sistémica, biodisponibilidad y semivida aparente, a partir de la caracterización farmacocinética publicada.

Scientific Overview

In short: GLP1-RC-TZ es un compuesto de investigación agonista dual de GIPR / GLP-1R, denominado habitualmente “Tirz” en comunidades de investigación.

Key research facts

Farmacología de receptores: actividad agonista dual GIPR / GLP-1R caracterizada en estudios in-vitro publicados

Se ha comunicado agonismo desequilibrado: potencia completa de GIPR con señalización de GLP-1R sesgada hacia cAMP frente al reclutamiento de β-arrestin

Sustituciones Aib2 y Aib13 investigadas por su resistencia a DPP-IV y proteasas

Se ha comunicado que la modificación C20 fatty-diacid proporciona una unión a albúmina del 99%; la semivida aparente de eliminación comunicada es de ~5 días

RCT SURMOUNT-1 (NEJM 2022, PMID 35658024), brazo de 15 mg: los investigadores comunicaron un cambio medio de −20.9% respecto al valor basal en el peso corporal en la semana 72

These points summarise lab themes, not human outcomes.

Los trabajos publicados caracterizan la farmacología de receptores, las modificaciones estructurales y el perfil farmacocinético de esta clase de compuestos, junto con variables definidas por protocolo investigadas en programas clínicos registrados.

La verificación de lotes de New-U y la literatura externa son conjuntos de evidencia independientes: los análisis del lote establecen la identidad analítica y la pureza del material analizado; los estudios publicados describen sus propios materiales y protocolos de investigación.

Arquitectura molecular

LY3298176 es un péptido sintético de 39 aminoácidos caracterizado en estudios de farmacología de receptores como agonista de dos incretin receptors, GLP-1R y GIPR, en lugar de GLP-1R solo.

Farmacología de receptores

La literatura describe el perfil como desequilibrado: potencia completa en GIPR superpuesta a una señal GLP-1R sesgada hacia cAMP. Tabla completa de vías: Receptor Pharmacology a continuación.

Modificaciones estructurales

Los trabajos estructurales publicados describen sustituciones Aib2 y Aib13 investigadas para resistencia a proteasas y un C20 fatty diacid unido a Lys20 mediante un espaciador γGlu/AEEA, investigado como contribuyente de unión a albúmina a una exposición sistémica prolongada.

Farmacocinética publicada

La semivida aparente de eliminación se sitúa en aproximadamente cinco días, con alrededor del 80% de biodisponibilidad subcutánea. Perfil completo: Pharmacokinetics a continuación.

Investigación clínica

Los hallazgos publicados resumidos en esta página se refieren a estudios clínicos externos del medicamento de referencia y a sus respectivos materiales y protocolos. No establecen la seguridad, eficacia ni equivalencia clínica del material GLP1-RC-TZ de New-U.

Referencias principales

Las publicaciones revisadas por pares y los registros de ensayos clínicos registrados se enumeran íntegramente, con identificadores DOI/PMID/NCT, en Source References a continuación.

At a glance

Mechanism and receptors Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Clinical research SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme.

Molecular characteristics Molecular weight 4,813.53 Da.

Pharmacokinetics Half-life: Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks.

Evidence maturity Tier 1: Human clinical — The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials.

Analytical verification Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Research limitations Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Receptor Pharmacology

Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GIPR Full agonist activity characterised experimentally, comparable to native GIP The arm that distinguishes the dual agonist from single GLP-1R compounds in the literature GLP-1R Agonist activity characterised as biased, favouring cAMP signalling over β-arrestin recruitment Investigated in relation to receptor desensitisation over prolonged exposure Adipose GIPR signalling Direct GIPR-mediated adipose effects characterised experimentally Investigated as a contributor to measured insulin-sensitivity markers and adiponectin Albumin-binding modification C20 eicosanedioic acid via a γGlu/AEEA spacer; 99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~5-day apparent half-life) Proteolytic stability Aib2 and Aib13 substitutions Structural modifications investigated for altered peptide stability against DPP-IV and proteases

Deeper dive for scientific readers

The imbalanced-agonism profile is characterised in JCI Insight (2020): full GIPR potency layered onto a cAMP-biased GLP-1R signal. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024) investigators reported a mean change from baseline in body weight of −20.9% at week 72 in the 15 mg arm. SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) was designed as a head-to-head comparison against semaglutide and reported −20.2% vs −13.7% at week 72. SURPASS-CVOT (NEJM 2025) compared cardiovascular outcomes against dulaglutide and reported an approximately 8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality. Insulin-sensitivity improvements beyond what change in body weight alone accounts for are discussed in the literature as consistent with direct GIPR-mediated adipose effects. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

¿Qué es Tirzepatide en investigación científica?

Tirzepatide (LY3298176) es un péptido sintético de 39 aminoácidos caracterizado en estudios de farmacología de receptores como agonista dual de los receptores GIP / GLP-1 con agonismo desequilibrado. Está aprobado como medicamento en algunas jurisdicciones bajo marcas de otros fabricantes; el material suministrado aquí no es ese producto farmacéutico terminado.

¿Qué es GLP1-RC-TZ?

GLP1-RC-TZ es el identificador de catálogo de New-U para el material de investigación de laboratorio ofrecido mediante este perfil de investigación. No es un medicamento, un tratamiento, un producto farmacéutico genérico ni un producto terapéutico, no es equivalente a ningún producto clínico o comercial y no se ofrece para uso humano ni veterinario.

¿Qué sistemas receptores se estudian en la investigación sobre Tirzepatide?

La farmacología in-vitro publicada caracteriza dos receptores: GIPR, donde la potencia agonista se comunica como comparable a GIP nativo, y GLP-1R, donde se comunica una señalización sesgada hacia la generación de cAMP frente al reclutamiento de β-arrestin. Los trabajos estructurales investigan además la modificación C20 fatty-diacid de unión a albúmina y las sustituciones Aib2/Aib13 para modificar la estabilidad proteolítica.

¿Qué análisis analíticos acompañan a GLP1-RC-TZ?

El Certificado de análisis publicado de GLP1-RC-TZ procede de un laboratorio analítico independiente y registra el laboratorio independiente, el número de informe, la pureza medida y la fecha del ensayo de la muestra analizada; el método y cualquier resultado de identidad figuran en el propio informe. Los viales no llevan marcado de lote, por lo que un certificado describe la muestra ensayada y no un vial o pedido concretos. El análisis de lote informa de la identidad y la pureza de la muestra ensayada. No establece esterilidad, endotoxinas ni contenido de metales pesados, equivalencia farmacéutica ni ninguna propiedad clínica.

¿Dónde puedo consultar el Certificado de análisis vigente de GLP1-RC-TZ?

El certificado vigente (laboratorio, número de informe, pureza medida y fecha del ensayo) se publica en /coa/tirzepatide, junto con el historial de ensayos del compuesto.

¿Qué significa una pureza HPLC >99%?

Es una cifra de pureza obtenida mediante reversed-phase high-performance liquid chromatography utilizando normalización de área: el pico objetivo representa más del 99% del área total integrada de picos del cromatograma de la muestra analizada. Es una afirmación únicamente sobre la pureza química de esa muestra y no dice nada sobre esterilidad, contenido de endotoxinas, equivalencia farmacéutica ni ninguna propiedad clínica.

¿Qué ensayos clínicos se citan en esta página?

Tres estudios externos del medicamento de referencia: SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024), SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) y SURPASS-CVOT (NEJM 2025; DOI 10.1056/NEJMoa2505928), junto con la caracterización de farmacología de receptores en JCI Insight (2020). Cada resultado comunicado en esta página se atribuye a su estudio, brazo y momento temporal.

¿Cómo se distingue la investigación clínica publicada de los análisis de lotes de New-U?

Son cuerpos de evidencia distintos. La investigación clínica publicada es un trabajo externo sobre el producto farmacéutico final aprobado, realizado conforme a los protocolos propios de esos estudios; no establece nada sobre el material suministrado aquí. Los ensayos de certificado de New-U son un trabajo analítico sobre una muestra enviada del material GLP1-RC-TZ: el informe publicado indica el resultado medido de la muestra analizada y no establece nada clínico. Un certificado de análisis combinado con un artículo clínico externo no equivale a una validación clínica de GLP1-RC-TZ.

¿Es GLP1-RC-TZ lo mismo que un medicamento de marca aprobado?

No. Los productos de marca aprobados de tirzepatide son productos farmacéuticos terminados estériles con receta, fabricados bajo cGMP por su titular de autorización de comercialización. GLP1-RC-TZ es material de investigación de laboratorio no aprobado suministrado como polvo liofilizado. No es equivalente, genérico ni sustituto de ningún producto aprobado.

¿Por qué Tirzepatide se describe como desequilibrado en la literatura?

Porque los dos brazos receptores no están equilibrados: la farmacología publicada comunica una potencia de agonista completo en GIPR comparable a GIP nativo, pero una señalización sesgada en GLP-1R que favorece la generación de cAMP frente al reclutamiento de β-arrestin. La literatura investiga esta asimetría en relación con la desensibilización del receptor durante exposiciones prolongadas.

¿En qué se diferencia la investigación sobre Tirzepatide de la investigación sobre Retatrutide y Semaglutide?

Según la cobertura de receptores caracterizada en la literatura: la investigación sobre semaglutide describe agonismo de GLP-1R, la investigación sobre tirzepatide describe agonismo de GIPR/GLP-1R y la investigación sobre retatrutide estudia agonismo de GLP-1R/GIPR/GCGR. Solo SURMOUNT-5 fue diseñado como comparación directa (tirzepatide vs semaglutide); los resultados obtenidos de programas independientes no son comparaciones directas.

¿En qué forma se suministra GLP1-RC-TZ?

GLP1-RC-TZ se suministra como polvo liofilizado en viales sellados, en packs de investigación sellados de 10 viales en las concentraciones indicadas; el Certificado de análisis se publica en la página del producto.

¿Cómo debe almacenarse el material de investigación de laboratorio?

Conservar el polvo liofilizado en un congelador a −20 °C. Si un protocolo de laboratorio requiere el material en solución, mantener la solución resultante refrigerada a 1–6 °C, protegida de la luz y evitar ciclos repetidos de congelación-descongelación, que pueden degradar la modificación de fatty-acid. Las condiciones de almacenamiento son únicamente información de manipulación de laboratorio.

Is Tirzepatide third-party tested?

Yes. Tirzepatide has an independent Janoshik Analytical Certificate of Analysis, which reports 99.899% purity for the sample analysed. The report number and test date are on the certificate, published on this page and on our COA page rather than packed with orders. View the Tirzepatide Certificate of Analysis →

Is it legal to buy Tirzepatide?

In the United States, Tirzepatide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks Absorption route Study protocols used subcutaneous administration; reported Tmax 8–72 h Bioavailability ~80% subcutaneous reported Metabolism / clearance Proteolytic backbone cleavage, β-oxidation of the C20 fatty-diacid chain and amide hydrolysis reported; metabolites eliminated ~66% renally / ~33% faecally; no CYP-mediated interactions Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~10.3 L; 99% albumin-bound. These are pharmacokinetic observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

SURMOUNT-1 RCT (Jastreboff et al., NEJM 2022; PMID 35658024), obesity/overweight population, 15 mg arm: investigators reported a mean change from baseline in body weight of −20.9% at week 72

SURMOUNT-5 head-to-head RCT (Aronne et al., NEJM 2025; PMID 40353578): investigators reported −20.2% in the tirzepatide arm vs −13.7% in the semaglutide arm at week 72

SURPASS-CVOT RCT (NEJM 2025), 13,000+ participants vs dulaglutide: investigators reported an ~8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality

SURPASS diabetes programme: investigators reported HbA1c reductions of up to 2.58% as a protocol-defined endpoint

Insulin-sensitivity markers and adiponectin recorded as measured endpoints, discussed in the literature in relation to direct GIPR-mediated adipose signalling

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The SURPASS and SURMOUNT programmes included 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg arms, with a protocol-defined step-up period of roughly 20 weeks before the maintenance arm level was reached. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Decreased appetite and dyspepsia recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Hypersensitivity and injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Tier 1 · Human clinical

SURMOUNT-1 obesity RCT — −20.9% mean change from baseline in body weight at week 72 (NEJM 2022; PMID 35658024)

SURMOUNT-5 head-to-head RCT vs semaglutide — −20.2% vs −13.7% at week 72 (NEJM 2025; PMID 40353578)

SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. · 2022 · PMID: 35658024 · DOI: 10.1056/NEJMoa2206038

Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. · 2025 · PMID: 40353578 · DOI: 10.1056/NEJMoa2416394

SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. · 2025 · DOI: 10.1056/NEJMoa2505928

PubMed: peer-reviewed literature on Tirzepatide

ClinicalTrials.gov: registered studies on Tirzepatide

Tirzepatide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

39-amino-acid synthetic peptide built on the GIP backbone (LY3298176)

Dual GIPR / GLP-1R agonist activity characterised with imbalanced agonism

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding

Apparent elimination half-life reported at approximately 5 days in published pharmacokinetic research

GLP1-RC-TZ laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

Identificador de catálogo de New-U GLP1-RC-TZ Objeto científico Tirzepatide (LY3298176) Peso molecular 4,813.53 Da Receptores caracterizados GIPR (agonista completo), GLP-1R (sesgado hacia cAMP) Pureza (analítica) >99% por normalización de área RP-HPLC Identidad (analítica) Se indica en el Certificado de análisis publicado cuando el informe incluye un ensayo de identidad Forma Polvo liofilizado Semivida publicada Aproximadamente 5 días, media de 116.7 h (investigación farmacocinética externa) Conservación Liofilizado: congelador a −20 °C. Reconstituido: 1-6 °C, protegido de la luz. Uso previsto Laboratory research material. Not for human or veterinary use.

Tirzepatide Research — GLP1-RC-TZ Laboratory Research Material

Tirzepatide is the most extensively characterised dual-incretin ("twincretin") peptide in the published literature. Receptor-pharmacology studies describe full GIPR agonist potency layered onto a cAMP-biased GLP-1R signal, and the clinical programme includes one trial, SURMOUNT-5 (NEJM 2025), specifically designed as a head-to-head comparison against semaglutide.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −20.9% at week 72 in the SURMOUNT-1 15 mg arm (NEJM 2022), −20.2% vs −13.7% against semaglutide at week 72 in SURMOUNT-5 (NEJM 2025), an ~8% relative reduction in major adverse cardiovascular events against dulaglutide in SURPASS-CVOT (NEJM 2025), and HbA1c reductions of up to 2.58% in the SURPASS programme. Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-TZ as lyophilised, analytically verified laboratory research material ; its published independent Certificate of Analysis records the independent laboratory, report number, measured purity and test date for the sample analysed. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material. GLP1-RC-TZ is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

Gastric inhibitory polypeptide - Wikipedia

Customer Reviews

Przejrzysty koszyk

Podobało mi się, że mogłem jeszcze raz sprawdzić ilość i wariant przed płatnością.

- Krzysztof S***** · 22 October 2026

Everything arrived safely

Order reached me in good condition and the contents matched the basket. All good here.

- Channan R***** · 20 October 2026

More in Metabolic Research

Metabolic Research Retatrutide Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Retatrutide →

Metabolic Research Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Semaglutide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Metabolic Research Liraglutide Liraglutide is a GLP-1 receptor agonist: a 31-residue analogue of GLP-1(7-37) with an Arg34 substitution and a C16 palmitoyl-γ-glutamate side chain on Lys26 that promotes albumin binding. Liraglutide →

Tirzepatide vs related Metabolic Research compounds

Compound Price Purity spec COA Tirzepatide from $221 >99% HPLC 2 published batches Retatrutide from $173 >99% HPLC 4 published batches Semaglutide from $111 >99% HPLC 1 published batch

Tirzepatide vs Retatrutide - full comparison

Tirzepatide vs Semaglutide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Tirzepatide

Metabolic Research research compounds

Tirzepatide research guide

Tirzepatide pricing and packs

Research this compound

Research guide Tirzepatide research guide Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural… Read the guide →

Compare Compare Tirzepatide and Liraglutide Tirzepatide vs Liraglutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Tirzepatide COA Latest published certificate of analysis (purity and identity), dated 2026-05-27. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research